AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20128336 — intervention group
Group type: COMPARATOR
Intervention: Control (C; n = 12)
Number of subjects: 24
Study 16466606 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 151
Study 16466606 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 151
Study 16466606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 16466606 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg and 40 mg
Number of subjects: 151
Study 15364675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 244
Study 15364675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 11316351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (40% VO2max) three times per week for 12 weeks in UB group
Number of subjects: 21
Study 11316351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (40% VO2max) three times per week for 12 weeks in LB group
Number of subjects: 21
Study 9042047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinalukast 10 mg
Number of subjects: 8
Study 9042047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinalukast 50 mg
Number of subjects: 8
Study 9042047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinalukast 200 mg
Number of subjects: 8
Study 9042047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7874603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (42 micrograms/nostril) administered three times a day for 8 weeks
Number of subjects: 228
Study 7874603 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times a day for 8 weeks
Number of subjects: 228
Study 7874603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 3280267 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior drainage through the abdominal wall
Number of subjects: 50
Study 3280267 — intervention group
Group type: COMPARATOR
Intervention: Posterior drainage through the buttocks
Number of subjects: 50
Study 3280267 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination of the sacral space due to rectum disrupture
Number of subjects: 50
Study 31738173 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrive intervention (n=181)
Number of subjects: 343
Study 28424359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 2.5/5 µg
Number of subjects: 586
Study 28424359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 5/5 µg
Number of subjects: 586
Study 28424359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol
Number of subjects: 586
Study 28424359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 25451471 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Pharyngeal Electrical Stimulation (PES) - 0.2‐ms pulses, 5 Hz, 280 V, stimulation intensity at 75% of maximum tolerated threshold
Number of subjects: 14
Study 25451471 — intervention group
Group type: COMPARATOR
Intervention: Sham Pharyngeal Electrical Stimulation (PES)
Number of subjects: 14
Study 25451471 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Pharyngeal Electrical Stimulation (PES)
Number of subjects: 14
Study 24149180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cediranib (20 mg)
Number of subjects: 582
Study 24149180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 582
Study 21080347 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 86
Study 21080347 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthopedic care
Number of subjects: 86
Study 20180668 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release methylphenidate combined with cognitive-behavioral therapy
Number of subjects: 303
Study 20180668 — intervention group
Group type: COMPARATOR
Intervention: Existing treatment program sources (treatment program staff, social services, juvenile justice system, mental health clinics)
Number of subjects: 303
Study 16876497 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum
Number of subjects: 23
Study 16876497 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (Vislube)
Number of subjects: 23
Study 12635391 — intervention group
Group type: COMPARATOR
Intervention: Gastric continuous enteral nutrition
Number of subjects: 43
Study 12635391 — intervention group
Group type: COMPARATOR
Intervention: Gastric intermittent enteral nutrition
Number of subjects: 43
Study 12635391 — intervention group
Group type: COMPARATOR
Intervention: Jejunal enteral nutrition
Number of subjects: 43
Study 10711608 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of the deciduous molar and mucogingival surgery (test site)
Number of subjects: 8
Study 10711608 — intervention group
Group type: COMPARATOR
Intervention: Extraction of the deciduous molar (control site)
Number of subjects: 8
Study 9085107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 0.5% eye drops
Number of subjects: 20
Study 9085107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7871046 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.28 g/kg alcohol
Number of subjects: 10
Study 7871046 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.36 g/kg alcohol
Number of subjects: 10
Study 7871046 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.54 g/kg alcohol
Number of subjects: 10
Study 7871046 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.72 g/kg alcohol
Number of subjects: 10
Study 7871046 — intervention group
Group type: COMPARATOR
Intervention: 0.00 g/kg (placebo)
Number of subjects: 10
Study 7871046 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alcohol doses
Number of subjects: 10
Study 3486625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 14
Study 3486625 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 14
Study 30159938 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist adherence
Number of subjects: 182
Study 30159938 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of clinical experience
Number of subjects: 182
Study 30159938 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence
Number of subjects: 182
Study 30159938 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence among therapists with formal CBT training
Number of subjects: 182
Study 27061779 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg) administered at 01:00, 03:00, 05:00, and 07:00 on both nights (total of 800 mg/night)
Number of subjects: 24
Study 27061779 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum administered at 01:00, 03:00, 05:00, and 07:00 on both nights
Number of subjects: 24
Study 25499937 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg self-administered via single 1 mL prefilled pen every 2 weeks (increased to 150 mg every 2 weeks at week 12 depending on LDL-C level)
Number of subjects: 314
Study 25499937 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day
Number of subjects: 314
Study 25499937 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day (statin rechallenge)
Number of subjects: 314
Study 22930768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered OSSEOTITE NT implants
Number of subjects: 20
Study 22930768 — intervention group
Group type: COMPARATOR
Intervention: Straight-walled OSSEOTITE implants
Number of subjects: 20
Study 21098467 — intervention group
Group type: EXPERIMENTAL
Intervention: European ancestry
Number of subjects: 4339
Study 18176291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-CHO)
Number of subjects: 95
Study 18176291 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 95
Study 15623809 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 266
Study 15623809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 12519877 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (T)
Number of subjects: 12
Study 12519877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10506405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a enteric-coated capsules (3 doses, every other day schedule)
Number of subjects: 0
Study 10506405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a liquid formulation (3 doses, every other day schedule)
Number of subjects: 0
Study 8777997 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg orally)
Number of subjects: 17
Study 8777997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8273531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic doses of propofol
Number of subjects: 0
Study 8273531 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 0
Study 8273531 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (Valium)
Number of subjects: 0
Study 2446752 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2 at 3-week intervals)
Number of subjects: 59
Study 2446752 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 at 3-week intervals) and Tamoxifen (10 mg twice per day)
Number of subjects: 59
Study 2446752 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and Tamoxifen
Number of subjects: 59
Study 29394449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO) diet
Number of subjects: 111
Study 29394449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (SO) diet
Number of subjects: 111
Study 26917606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 μg twice daily
Number of subjects: 751
Study 26917606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study 25691681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide 1.0-3.0 g/day (2-6 tablets/day)
Number of subjects: 644
Study 25691681 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer 2.4-14.4 g/day (3-18 tablets/day)
Number of subjects: 644
Study 25691681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide
Number of subjects: 644
Study 25691681 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 644
Study 25691681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 644
Study 24142086 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 637
Study 24142086 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (control group)
Number of subjects: 637
Study 20657177 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw‐HBVLT/Hib2.5 vaccine
Number of subjects: 192
Study 20657177 — intervention group
Group type: COMPARATOR
Intervention: DTPw‐HBV/Hib10 vaccine
Number of subjects: 192
Study 18258750 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant (0.5-600 mg)
Number of subjects: 24
Study 18258750 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant (0.5-600 mg) with high-fat meal
Number of subjects: 24
Study 17063345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine in combination with diet and lifestyle advice
Number of subjects: 8000
Study 17063345 — intervention group
Group type: COMPARATOR
Intervention: Diet and lifestyle advice alone (control)
Number of subjects: 8000
Study 12631097 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 20
Study 12631097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10570622 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg, 2 to 10 times daily) coadministered with levodopa/carbidopa or levodopa/benserazide
Number of subjects: 0
Study 10570622 — intervention group
Group type: COMPARATOR
Intervention: Entacapone
Number of subjects: 0
Study 7633695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) for 1 month
Number of subjects: 35
Study 7633695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NCPAP)
Number of subjects: 35
Study 2745343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl infusion (mean volume 1,280.3 +/- 107.3 ml)
Number of subjects: 9
Study 2745343 — intervention group
Group type: COMPARATOR
Intervention: No infusion (control)
Number of subjects: 9
Study 333077 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal sodium bicarbonate treatment (5 to 15 mEq bicarbonate/dl 10% glucose)
Number of subjects: 62
Study 333077 — intervention group
Group type: COMPARATOR
Intervention: Restricted sodium bicarbonate treatment
Number of subjects: 62
Study 31370154 — intervention group
Group type: EXPERIMENTAL
Intervention: FFE-50× at 200 mg
Number of subjects: 10
Study 31370154 — intervention group
Group type: EXPERIMENTAL
Intervention: FFE-10× at 1200 mg
Number of subjects: 10
Study 31370154 — intervention group
Group type: EXPERIMENTAL
Intervention: FFE-50× at 100 mg
Number of subjects: 10
Study 31370154 — intervention group
Group type: EXPERIMENTAL
Intervention: FFE-10× at 600 mg
Number of subjects: 10
Study 28365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 3 days (MGD3)
Number of subjects: 25
Study 28365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 7 days (MGD7)
Number of subjects: 25
Study 28365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 14 days (MGD14)
Number of subjects: 25
Study 28365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 21 days (MGD21)
Number of subjects: 25
Study 28365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement)
Number of subjects: 25
Study 28365118 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CTRL; 92% chopped grass hay and 8% mineral and vitamin supplement on a dry matter basis)
Number of subjects: 25
Study 25262164 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy (group A)
Number of subjects: 103
Study 25262164 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (group B)
Number of subjects: 103
Study 23088524 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan gels applied during the first 2 weeks after SRP (n = 17)
Number of subjects: 34
Study 23088524 — intervention group
Group type: COMPARATOR
Intervention: SRP only (control group, n = 17)
Number of subjects: 34
Study 23088524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 21282661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 120
Study 21282661 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise training)
Number of subjects: 120
Study 19141719 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital off‐loading silicone padding
Number of subjects: 89
Study 19141719 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 89
Study 16770728 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg daily for 6 weeks)
Number of subjects: 9
Study 16770728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 6 weeks)
Number of subjects: 9
Study 15309735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol perfusion group
Number of subjects: 100
Study 15309735 — intervention group
Group type: COMPARATOR
Intervention: Iodized oil perfusion group
Number of subjects: 100
Study 11512691 — intervention group
Group type: EXPERIMENTAL
Intervention: Late systolic wave observed in brachial artery Doppler study in CAD patients
Number of subjects: 96
Study 11512691 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects without late systolic wave
Number of subjects: 96
Study 11512691 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of risk factors
Number of subjects: 96
Study 8996149 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with six cycles of 5FU (425 mg/m2) plus leucovorin (20 mg/m2) by rapid intravenous injection daily for 5 consecutive days every 4 to 5 weeks
Number of subjects: 317
Study 8996149 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 317
Study 7837147 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating endothelin-1 (sET-1) levels in patients with diffuse systemic sclerosis (dSSc)
Number of subjects: 64
Study 7837147 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating endothelin-1 (sET-1) levels in patients with primary Raynaud's phenomenon (RP)
Number of subjects: 64
Study 7837147 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating endothelin-1 (sET-1) levels in patients with limited cutaneous systemic sclerosis (lcSSc) with hypertensive lung or renal disease
Number of subjects: 64
Study 7837147 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sET-1 levels with plasma von Willebrand factor (vWF), skin fibrosis (skin score), and duration of disease in patients with SSc
Number of subjects: 64
Study 7837147 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of sET-1 levels in diffuse cutaneous disease (dcSSc) with fibrotic dermal or lung pathology versus additional PHT or HRC crisis
Number of subjects: 64
Study 3367432 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial graft removal
Number of subjects: 75
Study 3367432 — intervention group
Group type: COMPARATOR
Intervention: Complete graft removal
Number of subjects: 75
Study 31980445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 412
Study 31980445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 31980445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia at 36 weeks postmenstrual age
Number of subjects: 412
Study 29202263 — intervention group
Group type: COMPARATOR
Intervention: Alloplast (n=11)
Number of subjects: 23
Study 29202263 — intervention group
Group type: COMPARATOR
Intervention: Allograft (n=12)
Number of subjects: 23
Study 29202263 — intervention group
Group type: COMPARATOR
Intervention: Alloplast (large particle size)
Number of subjects: 23
Study 29202263 — intervention group
Group type: COMPARATOR
Intervention: Allograft (large particle size)
Number of subjects: 23
Study 28582279 — intervention group
Group type: EXPERIMENTAL
Intervention: High NRG1 expression
Number of subjects: 208
Study 28582279 — intervention group
Group type: EXPERIMENTAL
Intervention: High HER3 expression
Number of subjects: 208
Study 28582279 — intervention group
Group type: EXPERIMENTAL
Intervention: High HER2/neu expression
Number of subjects: 208
Study 25307979 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 36
Study 25307979 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 36
Study 23343818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring muscle extensibility in maximal trunk flexion with knees flexed
Number of subjects: 75
Study 23343818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring muscle extensibility in sit-and-reach test for thoracic spine
Number of subjects: 75
Study 23343818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring muscle extensibility in sit-and-reach test for pelvic tilt
Number of subjects: 75
Study 23343818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring muscle extensibility in standing and on the bicycle postures
Number of subjects: 75
Study 21199130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg·kg(‐1) ketorolac IV
Number of subjects: 14
Study 21199130 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg·kg(‐1) ketorolac IV
Number of subjects: 14
Study 21199130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18272930 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) beverage
Number of subjects: 18
Study 18272930 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein (CHO+PRO) beverage
Number of subjects: 18
Study 18272930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) beverage
Number of subjects: 18
Study 16946218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal (dry) misoprostol 400 mug
Number of subjects: 40
Study 16946218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal (moistened) misoprostol 400 mug
Number of subjects: 40
Study 16946218 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 400 mug
Number of subjects: 40
Study 16946218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 400 mug
Number of subjects: 40
Study 12697917 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary interleukin-8 (IL-8) measurement
Number of subjects: 208
Study 10776826 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/day orally
Number of subjects: 3
Study 8615509 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 30
Study 8615509 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 30
Study 8615509 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium 0.2 mg/kg
Number of subjects: 30
Study 1598824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet A (300 mg ofloxacin)
Number of subjects: 12
Study 1598824 — intervention group
Group type: COMPARATOR
Intervention: Tablet B (300 mg ofloxacin)
Number of subjects: 12
Study 6507576 — intervention group
Group type: EXPERIMENTAL
Intervention: Armorlite Multiple Drop
Number of subjects: 11
Study 6507576 — intervention group
Group type: EXPERIMENTAL
Intervention: Signet Hyperaspheric
Number of subjects: 11
Study 6507576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sola Hi-Drop
Number of subjects: 11
Study 6507576 — intervention group
Group type: EXPERIMENTAL
Intervention: American Optical Fulvue
Number of subjects: 11
Study 6507576 — intervention group
Group type: COMPARATOR
Intervention: All lens types
Number of subjects: 11